Ancheta NO, Rodríguez SS, Matos TM, García del Barco HD, Alonso CM, Ancheta NH

Language: Spanish
References: 12
Page: 459-462
PDF size: 473.24 Kb.

ABSTRACT

Objective: to study the effect of GHRP6 on the ultrastructure of neurons and the peripheral processes of the spiral ganglion in a model of ototoxicity induced by Kanamycin.
Material and Method: male Wistar rats, with normal hearing, were divided into three groups. The control group, another group treated with Kanamycin and a third with GHRP6 plus Kanamycin. The obtained cochleas were prefixed by perfusion in the perilymphatic channel, with a mixture of Paraformaldehyde and Glutaraldehyde, then decalcified with EDTA and subsequently processed for study by Transmission Electron Microscopy.
Results: the neurons and peripheral processes of the spiral ganglion of the control group presented normal characteristics. In the Kanamycin group, we found alterations in the cells and peripheral processes. In the group treated with GHRP6, the ultrastructure of the neurons and the peripheral processes of the spiral ganglion showed better conservation.
Conclusions: The preservation of the ultrastructure of the neurons and the peripheral processes of the spiral ganglion treated with the GHRP6 leads us to consider the possible use of it to increase the benefits of cochlear implants in deaf individuals.

REFERENCES

1. Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Med Clin North Am. 2011;95(4):819-42, viii-ix.

2. Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. Hear Res. 2011;281(1-2):28-37.

3. Mac Dougall CaC, H.F. Chemotherapy and Microbial Diseases. Aminoglycosides. In: Brunton LL, editor. Goodman and Gilman´s The Pharmacological Basis of Therapeutics. Twelfth ed: Mc Graw Hill Medical; 2011. p. 1991.

4. Karasawa T, Steyger PS. Intracellular mechanisms of aminoglycoside-induced cytotoxicity. Integr Biol (Camb). 2011;3(9):879-86.

5. Op de Beeck K, Schacht J, Van Camp G. Apoptosis in acquired and genetic hearing impairment: the programmed death of the hair cell. Hear Res. 2011;281(1- 2):18-27.

6. Mukherjea D, Rybak LP, Sheehan KE, Kaur T, Ramkumar V, Jajoo S, et al. The design and screening of drugs to prevent acquired sensorineural hearing loss. Expert Opin Drug Discov. 2011;6(5):491-505.

7. Yorgason JG, Luxford W, Kalinec F. In vitro and in vivo models of drug ototoxicity: studying the mechanisms of a clinical problem. Expert Opin Drug Metab Toxicol. 2011;7(12):1521-34.

8. Wilson BS, Dorman MF. Cochlear implants: current designs and future possibilities. J Rehabil Res Dev. 2008;45(5):695-730.

9. Nichani J, Bruce IA, Mawman D, Khwaja S, Ramsden R, Green K. Cochlear implantation in patients deafened by ototoxic drugs. Cochlear implants international. 2013;14(4):207-12.

10. Pfingst BE, Bowling SA, Colesa DJ, Garadat SN, Raphael Y, Shibata SB, et al. Cochlear infrastructure for electrical hearing. Hear Res. 2011;281(1-2):65-73.

11. Berlanga-Acosta J., Abreu-Cruz A., García-del Barco Herrera D., Mendoza-Marí Y., Rodríguez-Ulloa A., García-Ojalvo A., Falcón-Cama V., Hernández-Bernal F., Beichen Q., Guillén-Nieto G. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the EvidencesSupporting Their Cytoprotective Effects. Clinical Medicine Insights: Cardiology11: 1–9, 2017.

12. Spurr AR. A low-viscosity epoxy resin embedding medium for electron microscopy. Journal of ultrastructure research. 1969; 26(1):31-43.